Jeffrey Wolf, MD

Clinical Professor, Department of Medicine, UCSF; and Director, Myeloma Program, UCSF Helen Diller Family Comprehensive Cancer Center

Phone: (415) 353-2421 (appts)
Box 0324, UCSF, San Francisco, CA 94143-0324

View on UCSF Profiles

Additional Websites

• Physician Referral Directory

Education

Washington University; St. Louis, Missouri, A.B., 1968, Chemistry
University of Illinois Medical Center, Chicago, IL, M.D., 1972
University of California, San Diego, Intern, 1972-1973, Internal Medicine
University of California, San Diego, Residency, 1973-1974, Internal Medicine
University of California, San Diego, Residency, 1975-1976, Internal Medicine
Fred Hutchinson Cancer Research Center, Seattle, Washington, Fellowship, January-February, 1977, Bone Marrow Transplantation
University of California San Francisco, San Francisco, Fellowship, 1976-1979, Hematology/Oncology

Professional Experience

• 1979-1982
  Staff Physician, City of Hope National Medical Center, Duarte, California, Hematology and Bone Marrow Transplantation
• 1982-2007
  Director of Stem Cell Transplantation Program, Practice of Hematology and Oncology, Alta Bates Summit Medical Center, Berkeley, California
• 2007-present
  Clinical Professor of Medicine, Division of Hematology/Oncology, University of California, San Francisco, California
• 2007-2010
  Director, Clinical Research, Division of Hematology/Oncology, University of California, San Francisco, California
• 2007-present
  Director, Myeloma Program, Division of Hematology/Oncology, University of California, San Francisco, California

Honors & Awards

• 1968-1972
  Bamberger Scholarship, University of Illinois, School of Medicine

Selected Publications

1. Wolf JL, Siegel D, Goldschmidt H, Hazell K, Bourquelot PM, Bengoudifa BR, Matous J, Vij R, de Magalhaes-Silverman M, Abonour R, Anderson KC, Lonial S. Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leuk Lymphoma. 2012 Sep; 53(9):1820-3.
   View on PubMed
2. Richardson PG, Badros AZ, Jagannath S, Tarantolo S, Wolf JL, Albitar M, Berman D, Messina M, Anderson KC. Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma. Br J Haematol. 2010 Aug; 150(4):428-37.
   View on PubMed
3. Kumar SK, Flinn I, Noga SJ, Hari P, Rifkin R, Callander N, Bhandari M, Wolf JL, Gasparetto C, Krishnan A, Grosman D, Glass J, Sahovic EA, Shi H, Webb IJ, Richardson PG, Rajkumar SV. Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study. Leukemia. 2010 Jul; 24(7):1350-6.
   View on PubMed
4. Kavanagh JJ, Levenback CF, Ramirez PT, Wolf JL, Moore CL, Jones MR, Meng L, Brown GL, Bast RC. Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer. J Hematol Oncol. 2010; 3:9.
   View on PubMed
5. Layzer R, Wolf J. Myeloma-associated polyneuropathy responding to lenalidomide. Neurology. 2009 Sep 8; 73(10):812-3.
   View on PubMed
6. Jagannath S, Durie BG, Wolf JL, Camacho ES, Irwin D, Lutzky J, McKinley M, Potts P, Gabayan AE, Mazumder A, Crowley J, Vescio R. Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma. Br J Haematol. 2009 Sep; 146(6):619-26.
   View on PubMed
7. Wolf J, Richardson PG, Schuster M, LeBlanc A, Walters IB, Battleman DS. Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series. Clin Adv Hematol Oncol. 2008 Oct; 6(10):755-60.
   View on PubMed
8. Jagannath S, Durie BG, Wolf J, Camacho E, Irwin D, Lutzky J, McKinley M, Gabayan E, Mazumder A, Schenkein D, Crowley J. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol. 2005 Jun; 129(6):776-83.
   View on PubMed
9. Linker CA, Damon LE, Ries CA, Navarro WA, Case D, Wolf JL. Autologous stem cell transplantation for advanced acute myeloid leukemia. Bone Marrow Transplant. 2002 Feb; 29(4):297-301.
   View on PubMed
10. Govberg IJ, Wolf JL, Cotter PD. Trisomy 4 and double minutes in acute myeloid leukemia: further evidence that double minutes can occur as the primary cytogenetic abnormality. Cancer Genet Cytogenet. 2000 Sep; 121(2):212-5.
    View on PubMed
11. Damon LE, Wolf JL, Rugo HS, Gold E, Zander AR, Cassidy M, Cecchi G, Cohen N, Irwin D, Tracy M, Ries CA, Linker CA. High-dose chemotherapy (CTM) for breast cancer. Bone Marrow Transplant. 2000 Aug; 26(3):257-68.
    View on PubMed
12. McGhee EM, Cohen NR, Wolf JL, Ledesma CT, Cotter PD. Monosomy 16 as the sole abnormality in myeloid malignancies. Cancer Genet Cytogenet. 2000 Apr 15; 118(2):163-6.
    View on PubMed
13. Damon LE, Hu WW, Stockerl-Goldstein KE, Blume KG, Wolf JL, Gold E, Cecchi GR, Irwin D, Glaspy J, Territo I, Miller W, Mason JR, Linker CA. High-dose chemotherapy and hematopoietic stem cell rescue for breast cancer: experience in California. Biol Blood Marrow Transplant. 2000; 6(5):496-505.
    View on PubMed
14. Linker CA, Ries CA, Damon LE, Rugo HS, Wolf JL. Autologous bone marrow transplantation for acute myeloid leukemia using 4-hydroperoxycyclophosphamide-purged bone marrow and the busulfan/etoposide preparative regimen: a follow-up report. Bone Marrow Transplant. 1998 Nov; 22(9):865-72.
    View on PubMed
15. Lienert-Weidenbach K, Valiante NM, Brown C, White C, Johnston-Dow L, McGinnis M, Krausa P, Lakes DM, Wolf JL, Blume KG, Parham P. Mismatches for two major and one minor histocompatibility antigen correlate with a patient's rejection of a bone marrow graft from a serologically HLA-identical sibling. Biol Blood Marrow Transplant. 1997 Nov; 3(5):255-60.
    View on PubMed
16. Rugo HS, Damon LE, Ries CA, Wolf JL, Linker CA. High-dose chemotherapy for peripheral stem cell procurement in leukemia, lymphoma and multiple myeloma. Prog Clin Biol Res. 1994; 389:505-11.
    View on PubMed
17. Linker CA, Damon LE, Ries CA, Rugo HS, Wolf JL. Busulfan plus etoposide as a preparative regimen for autologous bone marrow transplantation for acute myelogenous leukemia: an update. Semin Oncol. 1993 Aug; 20(4 Suppl 4):40-8; quiz 49.
    View on PubMed
18. Linker CA, Ries CA, Damon LE, Rugo HS, Wolf JL. Autologous bone marrow transplantation for acute myeloid leukemia using busulfan plus etoposide as a preparative regimen. Blood. 1993 Jan 15; 81(2):311-8.
    View on PubMed
19. Wolf JL. Why antigens are attracted to the dome epithelium: another clue. Gastroenterology. 1988 Nov; 95(5):1419-21.
    View on PubMed
20. Rybicki AC, Heath R, Wolf JL, Lubin B, Schwartz RS. Deficiency of protein 4.2 in erythrocytes from a patient with a Coombs negative hemolytic anemia. Evidence for a role of protein 4.2 in stabilizing ankyrin on the membrane. J Clin Invest. 1988 Mar; 81(3):893-901.
    View on PubMed

View on UCSF Profiles